Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NRX Pharmaceuticals, Inc.NRXP · Entity 6523 | Director | April 09, 2025 | September 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NRX Pharmaceuticals, Inc.
Report date April 09, 2025 · Filed September 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2035-04-09 | Direct | 50,000 |
Reported balance
After 2025-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-09 · Grant · Acquired 50,000 · Balance 50,000 F1: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2025 Filed Sep 10, 2025 15:34 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001415889-25-024081 · form4-09102025_070918.xml · derivative · entry 1 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-04-09 F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 1,750 | $1.25 | $2,187.50 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 5 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.24 | $3,100.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 4 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,209 F4 · ownership.nature: Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.25 | $3,125.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 3 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 37,709 F3 · ownership.nature: Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.25 | $3,125.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 2 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,209 F2 · ownership.nature: Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.25 | $3,125.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 1 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 37,709 F1 · ownership.nature: Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| October 21, 2022 Filed Nov 22, 2022 17:44 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantEmployee Stock Option · Derivative | 162,660 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000950142-22-003242 · es220307154_4-flynnp.xml · derivative · entry 1 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,660 Underlying: Common Stock · 162,660 shares Expires 2032-10-21 F1 · price: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. F1 · derivative.exercise_date: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:46 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock Warrant (Right to buy) · Derivative | 692,639 | Not disclosed Strike: $3.08 | Not disclosed |
DisclosureSEC source: 0000950142-21-001938 · es210157182_4-flynnp.xml · derivative · entry 5 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 692,639 Underlying: Common Stock · 692,639 shares Expires 2025-10-22 F6 · price: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement). F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement). F5 · ownership.nature: Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:46 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock Warrant (Right to buy) · Derivative | 692,639 | Not disclosed Strike: $3.08 | Not disclosed |
DisclosureSEC source: 0000950142-21-001938 · es210157182_4-flynnp.xml · derivative · entry 4 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 692,639 Underlying: Common Stock · 692,639 shares Expires 2025-10-22 F6 · price: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement). F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement). F4 · ownership.nature: Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:46 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock | 35,209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-001938 · es210157182_4-flynnp.xml · nonDerivative · entry 3 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 35,209 F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement). F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger. F5 · ownership.nature: Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:46 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock | 35,209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-001938 · es210157182_4-flynnp.xml · nonDerivative · entry 2 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 35,209 F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement). F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger. F4 · ownership.nature: Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:46 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock | 362,332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-001938 · es210157182_4-flynnp.xml · nonDerivative · entry 1 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 362,332 F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement). F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger. F3 · ownership.nature: Held by Nash-Flynn Investments, LLC of which the Reporting Person is the sole member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.